About Melanoma-associated antigen E2
Melanoma-associated antigen E2 (MAGEE2) is a protein
from Homo sapiens identified by UniProt accession
Q8TD90, 523 residues long.
MolForge cross-references it against 0 known binders and
7 disease associations.
Target properties
| Protein name | Melanoma-associated antigen E2 |
|---|
| UniProt accession | Q8TD90 |
|---|
| Gene | MAGEE2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 523 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (7)
Diseases linked to this target (Open Targets).
- 3-hydroxy-1-methylpropylmercapturic acid measurement · score 0.06
- mean corpuscular volume · score 0.03
- potassium measurement · score 0.02
- COVID-19 · score 0.01
- neoplasm · score 0.01
- cancer · score 0.00
- migraine disorder · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8TD90-F1 | alphafold | PREDICTED | 72.39 | — |
Amino-acid sequence (523 residues)
MSLVSQNARH CSAEITADYG DGRGEIQATN ASGSPTSMLV VDAPQCPQAP INSQCVNTSQ AVQDPNDLEV LIDEQSRRLG ALRVHDPLED RSIALVNFMR MKSQTEGSIQ QSEMLEFLRE YSDQFPEILR RASAHLDQVF GLNLRVIDPQ ADTYNLVSKR GFQITDRIAE SLDMPKASLL ALVLGHILLN GNRAREASIW DLLLKVDMWD KPQRINNLFG NTRNLLTTDF VCMRFLEYWP VYGTNPLEFE FLWGSRAHRE ITKMEALKFV SDAHDEEPWS WPEEYNKALE GDKTKERSLT AGLEFWSEDT MNDKANDLVQ LAISVTEEML PIHQDELLAH TGKEFEDVFP NILNRATLIL DMFYGLSLIE VDTSEHIYLL VQQPESEEEQ VMLESLGRPT QEYVMPILGL IFLMGNRVKE ANVWNLLRRF SVDVGRKHSI TRKLMRQRYL ECRPLSYSNP VEYELLWGPR AHHETIKMKV LEYMARLYRK RPQNWPEQYR EAVEDEEARA KSEATIMFFL DPT
Explore Melanoma-associated antigen E2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets